Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004048 · ClinicalTrials.gov registry record · Phase 1

Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer

A Phase 1 study of Head and Neck Cancer, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT00004048: Completed Phase 1 study of Head and Neck Cancer, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.

NCT00004048 is a Phase 1 study of Head and Neck Cancer that has completed, run by Garden State Cancer Center at the Center for Molecular Medicine and Immunology. The registered enrollment target is 30 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004048, a Phase 1 study of Head and Neck Cancer, has completed, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by radioimmunotherapy or chemotherapy used to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radioimmunotherapy with or without doxorubicin plus peripheral stem cell transplantation in treating patients who have thyroid cancer.

Conditions Studied

Head and Neck Cancer

Interventions

  • PROCEDURE peripheral blood stem cell transplantation
  • BIOLOGICAL filgrastim
  • DRUG doxorubicin hydrochloride
  • PROCEDURE autologous bone marrow transplantation
  • RADIATION indium In 111 monoclonal antibody MN-14

Study Locations (2)

New Jersey

  • Garden State Cancer Center - Belleville
  • St. Joseph's Hospital and Medical Center - Paterson

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 1998-09
Est. Completion 2002-05
Phase Phase 1
Garden State Cancer Center at the Center for Molecular Medicine and Immunology

6 total trials

What the finished NCT00004048 record still lists

NCT00004048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 5 interventions - of which peripheral blood stem cell transplantation is the first listed.

NCT00004048 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00004048 about?

NCT00004048 is a clinical study titled "Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace ...

What is the current status of trial NCT00004048?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1998-09. Estimated completion is 2002-05.

What conditions does trial NCT00004048 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT00004048?

The interventions under investigation include: peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), autologous bone marrow transplantation (PROCEDURE), indium In 111 monoclonal antibody MN-14 (RADIATION).

Who is sponsoring clinical trial NCT00004048?

This trial is sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004048 being conducted?

This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00004048's enrollment target sits among peer trials

30 174th of 250 higher than 66 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00004048, the US trial registry maintained by the National Library of Medicine. NCT00004048 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.